Literature DB >> 8740692

Analysis of phosducin as a candidate gene for retinopathies.

F Ara-Iwata1, S G Jacobson, J D Gass, Y Hotta, K Fujiki, M Hayakawa, G Inana.   

Abstract

Phosducin, a retina-expressed gene mapped to chromosome 1q25-32.1, was analyzed as a candidate gene for retinopathies. The phosducin gene was cloned and characterized, and PCR primers were designed. Eighty-three patients with various retinopathies and 45 control subjects (24 American, 21 Japanese) were analyzed for mutations in the phosducin gene by PCR, denaturing gradient gel electrophoresis (DGGE), and sequencing. A heterozygous sequence variant changing a glycine to arginine at codon 178 was found in one Usher syndrome type II (USH2) patient, while the other USH2 patients did not show any coding sequence variant. A heterozygous sequence variant changing an asparagine to lysine at codon 174 was found in a patient with a severe retinal degeneration in the category of diseases known as acute zonal occult outer retinopathy (AZOOR). Three non-coding sequence variants were found. Two of these were always present together and found in 20.8% of American and 2.4% of Japanese control subjects, reflecting a difference in population pools. In conclusion, the phosducin gene did not show mutations consistent with it being the causative gene for USH2, but its possible pathogenicity in AZOOR or other retinopathies remains an open question which may be answered by further analysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740692     DOI: 10.3109/13816819609057863

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  2 in total

Review 1.  The physiological roles of phosducin: from retinal function to stress-dependent hypertension.

Authors:  Nadine Beetz; Lutz Hein
Journal:  Cell Mol Life Sci       Date:  2010-10-31       Impact factor: 9.261

Review 2.  Phosducin - a candidate gene for stress-dependent hypertension.

Authors:  Guido Grassi
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.